S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
MIAMI BEACH, Fla. - AirSculpt Technologies, Inc. (NASDAQ:AIRS), a provider of premium body contouring procedures with a market capitalization of $298 million, has launched a public offering of 3.16 million shares of common stock, with an additional option for the underwriter to purchase up to 474,000 more shares within 30 days. The entire stock offering is sold by the company itself. The stock has shown significant momentum, gaining nearly 14% in the past week according to InvestingPro data.
Vesey Street Capital Partners, L.L.C., associated with two directors and the largest shareholder of AirSculpt, has indicated an interest in acquiring up to $4.0 million worth of shares. However, this expression of interest is non-binding and may not result in an actual purchase. The company plans to allocate the net proceeds from the offering towards repaying a portion of its outstanding debt under its existing credit agreement, with the remainder for general corporate purposes, including working capital and other business ventures. InvestingPro analysis reveals the company’s current ratio of 0.57 indicates short-term obligations exceed liquid assets, making this debt management crucial.
Leerink Partners LLC is serving as the sole book-running manager for the offering. The shares are available under a shelf registration statement that was declared effective on March 24, 2025, by the Securities and Exchange Commission (SEC). Interested parties can obtain the preliminary prospectus supplement and accompanying prospectus from the SEC’s website or directly from Leerink Partners.
AirSculpt specializes in minimally invasive body contouring treatments that emphasize comfort and precision, providing quick recovery and precise sculpting results. The treatment is exclusively available at AirSculpt offices. Despite maintaining a strong gross profit margin of 64%, InvestingPro data shows the company is not currently profitable, with analysts expecting continued challenges this year. For deeper insights into AirSculpt’s financial health and future prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
The press release includes forward-looking statements regarding the timing, size, and completion of the offering, the intended use of proceeds, and other non-historical information. These statements are predictions based on current expectations and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially. With a beta of 2.51, the stock shows significantly higher volatility than the overall market, making it particularly sensitive to market conditions, completion of the offering, and various risks outlined in the company’s SEC filings.
Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. The information in this article is based on a press release statement from AirSculpt Technologies.
In other recent news, AirSculpt Technologies reported its first-quarter 2025 financial results, revealing a revenue of $39.4 million, a 17.3% decline from the previous year. Despite this decrease, the company exceeded earnings expectations with an earnings per share (EPS) of -$0.02, compared to the forecasted -$0.0333. The company has provided a revenue guidance of $160-170 million for the year 2025, with an adjusted EBITDA target of $16-18 million. AirSculpt Technologies also announced the results of its 2025 annual meeting of stockholders, where two Class I director nominees, Yogi Jashnani and Daniel Sollof, were elected to serve for a three-year term. Additionally, Grant Thornton was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The recent stockholder meeting highlighted strong support for the elected directors and the appointed auditor. The company is implementing strategic adjustments, including workforce reductions and marketing reallocations, expected to save $3 million annually. AirSculpt Technologies is not anticipating significant revenue from its new skin tightening pilot in 2025, but remains focused on enhancing marketing efficiency and expanding financing options to improve case conversion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.